DMRA — Damora Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1800315 ·
Last close
$22.56
Market Cap
$1.40B
52W High
$38.33
52W Low
$15.76
ADV30
483,140
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -36,863,000 -31,991,000 532,627,000 349,656,000 36,866,000
Jun 2026 0 — -34,994,000 -31,174,000 543,636,000 540,515,000 27,577,000
Mar 2026 0 — -30,811,000 -27,783,000 535,442,000 532,899,000 23,839,000
Dec 2025 0 — -201,696,000 -200,736,000 260,527,000 257,624,000 20,147,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-59,133,000
Investing CF
$-17,374,000
Financing CF
$330,545,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.77
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-578,311,000
Inventory
—
Receivables
$838,000
ST Investments
$178,822,000
EBIT TTM
$-304,364,000
Pretax Income TTM
$-291,343,000
Interest Exp TTM
—
Analysts
9

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -210,872,000 -209,839,000 260,527,000 20,147,000 240,380,000 -6,726,000
Dec 2024 0 -21,292,000 -21,439,000 17,132,000 1,301,000 15,831,000 -18,623,000
Dec 2023 0 -36,457,000 -38,349,000 38,227,000 5,896,000 32,331,000 -36,911,000
Dec 2022 0 -61,207,000 -61,624,000 73,188,000 11,435,000 61,753,000 -42,932,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-262,826,000
OpCashFlow TTM
—
Assets (Latest)
$543,636,000
Forward EPS
$-2.17

Peers — same industry

TickerNameMarket CapLastDaily %
NBTX Nanobiotix S.A. $1.39B $27.45 —
RAPP Rapport Therapeutics, Inc. $1.41B $23.76 —
NUVB Nuvation Bio Inc. $1.37B $3.90 —
ANAB ANAPTYSBIO, INC $1.36B $45.61 —
TYRA Tyra Biosciences, Inc. $1.35B $19.57 —

News headlines (Yahoo Finance, 1h cache)

Should Trial Launch Require Action From Damora Therapeutics (DMRA) Investors?
2026-11-06 03:19 · Yahoo
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-05 21:01 · Yahoo
Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
2026-11-04 21:06 · Yahoo
Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at
2026-11-04 14:00 · Yahoo
Damora Therapeutics (DMRA) Stock Looks Above Fair Value On Book Value
2026-10-10 14:21 · Yahoo
Damora Therapeutics (DMRA) Climbed, So What Is Drawing Attention Now?
2026-10-10 05:10 · Yahoo
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-08-10 20:05 · Yahoo
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
2026-08-05 12:00 · Yahoo
Damora Announces Redomestication from Delaware to Cayman Islands
2026-07-17 12:00 · Yahoo
Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer
2026-05-05 17:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.